Early marker for Alzheimer's disease: Hippocampus T1rho (T1ρ) estimation
✍ Scribed by Mohammad Haris; Erin McArdle; Matthew Fenty; Anup Singh; Christos Davatzikos; John Q. Trojanowski; Elias R. Melhem; Christopher M. Clark; Arijitt Borthakur
- Book ID
- 102375434
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 186 KB
- Volume
- 29
- Category
- Article
- ISSN
- 1053-1807
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Purpose
To evaluate the T1rho (T~1ρ~) MRI relaxation time in hippocampus in the brain of Alzheimer's disease (AD), mild cognitive impairment (MCI), and control, and to determine whether the T~1ρ~ shows any significant difference between these cohorts.
Materials and Methods
With informed consent, AD (n = 49), MCI (n = 48), and age‐matched control (n = 31) underwent T~1ρ~ MRI on a Siemens 1.5T Scanner. T~1ρ~ values were automatically calculated from the left and right hippocampus region using in‐house developed software. Bonferroni post‐hoc multiple comparisons was performed to compare the T~1ρ~ value among the different cohorts.
Results
Significantly higher T~1ρ~ values were observed both in AD (P = 0.000) and MCI (P = 0.037) cohorts compared to control; also, the T~1ρ~ in AD was significantly high over (P = 0.032) MCI. Hippocampus T~1ρ~ was 13% greater in the AD patients than control, while in MCI it was 7% greater than control. Hippocampus T~1ρ~ in AD patients was 6% greater than MCI.
Conclusion
Higher hippocampus T~1ρ~ values in the AD patients might be associated with the increased plaques burden. A follow‐up study would help to determine the efficacy of T~1ρ~ values as a predictor of developing AD in the control and MCI individuals. J. Magn. Reson. Imaging 2009;29:1008–1012. © 2009 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract A key question in designing MRI‐based clinical trials is how the main magnetic field strength of the scanner affects the power to detect disease effects. In 110 subjects scanned longitudinally at both 3.0 and 1.5 T, including 24 patients with Alzheimer's Disease (AD) [74.8 ± 9.2 years,